Latest news with #Volini
Economic Times
3 days ago
- Health
- Economic Times
Sprays, pills, creams...ooh, aah, ouch? India's pain market is now a Rs 16,000 cr giant
Synopsis India's pain relief market has exploded post-pandemic, doubling to nearly ₹16,000 crore in just five years. From gels and sprays to pills like Dolo and Zerodol, pain meds are now a daily fix for everything from gym soreness to chronic stress. The shift is lifestyle-driven and increasingly normalised, but experts warn against unchecked self-medication. As the over-the-counter space booms, driven by awareness and ease of access, the line between relief and risk is getting worryingly thin. Agencies Mumbai: Indians are increasingly popping over-the-counter pills, using sprays or rubbing in creams to soothe their aches and pains, adding more than a billion dollars to the pain management market over the past five years. The category is the biggest within the non-prescription segment, and has seen about five brands launched every week on average since the pandemic, industry executives said, citing Nielsen data. There were 1,552 brands -including Volini, Omnigel, Dolo and Saridon -to tackle the twinges in 2020; now, there are 2,771. Consumers are more attentive to alleviating any pain on a more immediate basis, said Shivam Puri, managing director at Cipla Health, which sells the biggest rubefacient brand, Omnigel. Rubefacient are gels and creams for topical application. "Rise of urbanisation and increase in chronic illnesses have led to the need for faster, more convenient formats that are accessible across platforms," said Puri. This is despite medical professionals advising caution on random use of painkillers. The pain relief category is often lifestyle-driven in urban markets, especially with gym and sports injuries. As a result, the market for analgesics (pain relief medication) and rubefacient more than doubled to ₹15,905 crore as of May this year, from ₹6,820 crore as of May 2020, growing at a compounded annual rate of 18%. This is three times faster than overall over-the-counter market growth, which rose at 6% CAGR to ₹80,000 crore. Analgesics account for 75% of the pain medication market and within analgesics, paracetamol is the biggest contributor, according to data from market researcher PharmaTrac. Covid has changed Indians' views on pain management, said Sandeep Verma, head for consumer health business for South Asia at Bayer Pharmaceuticals, which sells Saridon. 'A lot of Indians view taking pain relief medication as a sign of weakness or worry about becoming dependent on it. Covid made many of us more aware of how stress, exhaustion, and even mild but recurring pain can chip away at our wellbeing and productivity,' he said.'More people are starting to understand that living with untreated pain impacts their quality of life."Experts said pain management medications are also used to treat inflammation and adjacent issues, widening the need for the pills.'The analgesic segment that is dominated by paracetamols has been growing at a steady rate of 10%. This is because paracetamol medications are taken alongside other conditions that could include arthritis, any other bacterial or viral infection,' said Sheetal Sapale, vice president, commercial, at Kumar Sinha, consultant physician at Mumbai-based WeCare Wellness, said lifestyle-related problems — including rising stress levels, lack of sleep and increasing obesity — are reasons for increasing demand for pain medications.'Lack of physical exercise, increase in body weight leading to knee and joint pain, anxiety, depression are all causes of increase in body pain, headaches or migraine,' he said.'There is also an increase in people doing self-medication and several mandatory prescription drugs, strong painkillers and anti-inflammatory medications — that can have severe harmful effects, such as damage to the kidneys, if used over a prolonged period — are today available easily at chemist shops without prescriptions,' said top-selling drugs in the pain category are IPCA's Zerodol SP, Janssen's Ultracet, GSK's Calpol, Micro Lab's Dolo, Torrent's Chymoral Forte and Cipla's Ibugesic Plus. A majority of them are prescription pain is not the only category that people are self-medicating in since the pandemic. Skin creams, earlier prescribed by dermatologists, are drawing a consumer base, especially Gen Z products, which treat scalp and skin issues and form the second biggest category after pain, expanded 8% CAGR over the past five years and are now a ₹14,854 crore Prakash, partner and healthcare services industry leader at Grant Thornton, said, 'Over-the-counter as a segment has grown post-Covid because of more knowledge and information for categories including anti-allergic medications, skin creams, tear drops among others.'
Time of India
14-07-2025
- Sport
- Time of India
Jannik Sinner clostebol controversy: What is this drug and why are some tennis fans angry
Jannik Sinner has just lived out the kind of script Hollywood might reject for being too on the nose: young prodigy, doping cloud, short ban, glorious return, and finally, the crown jewel — a Wimbledon title on the hallowed grass of Centre Court. He didn't just beat Carlos Alcaraz in the final; he beat Novak Djokovic in the semis — the man who's made a second career out of destroying generational dreams. And yet, for many watching, the taste is bittersweet. Because running parallel to the fairytale is the quiet but persistent question: what about the drugs? No, not syringes-in-the-locker-room kind of drugs. Just a whisper of Clostebol — a name that sounds more like a cough syrup than a career-altering compound. But in sport, as in politics, it's not the crime; it's the chemical. So, what on earth is Clostebol? Clostebol is a synthetic anabolic steroid, essentially a Frankenstein cousin of testosterone with just enough bite to help muscle recovery, but not enough to turn you into Ivan Drago. Think of it as the steroid equivalent of a smart casual dress code: won't win you a bodybuilding contest, but may give you an edge in a five-set war of attrition. It's often used in topical creams in parts of Europe to treat wounds, ulcers, and skin abrasions. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Đây có thể là thời điểm tốt nhất để giao dịch vàng trong 5 năm qua IC Markets Tìm hiểu thêm Undo In Italy, Trofodermin — a clostebol-based ointment — is as common as Volini is in Indian households. So yes, it's medically legitimate. But in sports? Completely banned. No exceptions. Not even for a scraped shin or your physio's poor hygiene. The Sinner saga: Contamination, conviction, and comeback Sinner tested positive for Clostebol in March 2024 — twice, in fact. But not in your usual doping scandal fashion. According to his team, the steroid didn't come from pills or injections, but from his physiotherapist's cut finger. Yes, really. Apparently, the physio had been using a clostebol-laced cream on himself and then massaged Sinner's legs without gloves. Nine days of leg massages later, the world's top-ranked player had enough trace amounts in his system to show up on a drug test. Microscopic levels — picograms. A trillionth of a gram. You'd find more chemical residue in a municipal swimming pool. Anti-doping authorities believed the explanation. Sort of. They ruled he bore no significant fault, stripped him of his Indian Wells prize money, and then quietly negotiated a three-month suspension — a sort of sporting house arrest. Sinner took the ban, did the time, and returned just in time to storm through the clay and grass seasons. Now he's Wimbledon champion. The ghosts of tennis past: Enter Agassi, with meth If all this sounds surreal, remember: tennis has been here before. In the late 1990s, Andre Agassi tested positive for methamphetamine — yes, the same stuff that fuels Breaking Bad plotlines. He blamed it on a spiked soda from his assistant 'Slim' (yes, really), and the ATP, in a fit of convenient bureaucracy, accepted the excuse and buried the result. It didn't come out until Agassi admitted it in his 2009 memoir, Open, turning a potentially career-ending scandal into a literary redemption arc. Sinner's case isn't nearly as dramatic — no crystal meth, no faux-cocaine denial — but the echoes are unmistakable. Tennis has always had a peculiar relationship with drug use. It forgives quietly, forgets efficiently, and moves on gracefully — preferably in white. Why fans are divided To Sinner's supporters, this is a non-story. A nothingburger served cold. He didn't cheat, didn't inject, didn't knowingly dope. He explained, he cooperated, he accepted a suspension. Move on. But to critics, the issue isn't what Sinner did — it's what the system allows. A three-month slap on the wrist for a banned substance, a return timed perfectly for the Grand Slams, and now a standing ovation at Wimbledon. If the same had happened to a lower-ranked player, would the outcome have been so lenient? If the banned substance had been found in, say, an Eastern European wild card, would the public discourse be so forgiving? And most damning of all: if Novak Djokovic had tested positive for clostebol, would anyone believe the 'accidental cream contamination' narrative? The larger dilemma: Intent vs presence Anti-doping rules are built on strict liability — you're responsible for what's in your body, regardless of intent. But elite sport often muddies the water. Intent becomes a legal grey zone, contamination becomes plausible deniability, and reputation often sways judgment more than science. Clostebol, by itself, won't make you a Grand Slam champion. But it might help you recover a little faster, push a little harder, get through that fifth set with a bit more gas in the tank. And in a sport where margins are everything — a foot fault here, a net cord there — that matters. So, is Sinner's Wimbledon win tainted? Officially? No. He served his time. He's clean. He's earned it. Culturally? That's trickier. This is tennis, after all — a sport that prizes elegance, tradition, and the illusion of perfection. A grass court is sacred. A champion is supposed to be not just victorious, but virtuous. Sinner's win may be legitimate, but for some fans, it's no longer immaculate. And in the end, perhaps that's the true cost of Clostebol — not the suspension, not the missed points, but the asterisk some will always see, even if it's written in invisible ink. Wimbledon 2025 may have a new king. But the crown, as always, weighs heavy — especially when there's steroid cream on the throne.
India.com
20-06-2025
- Business
- India.com
Meet woman, daughter of India's richest pharma tycoon, she now leads Rs 3950000000000 company, she is…, her business is…
Vidhi Shanghvi, Sun Pharma Vidhi Shanghvi is daughter of Dilip Shanghvi, a famous Pharma businessman. She is in headlines for her role in Sun Pharma, one of India's biggest pharmaceutical companies. His net worth is around $25 billion and known as India's richest pharma billionaire. He is also among the top 100 richest people in the world. But now, his daughter Vidhi Shanghvi has also started handling his business. Who Is Vidhi Shanghvi? Vidhi Shanghvi is an Executive Director in Sun Pharma. After 13 years of experience, she now leads Sun Pharma's Consumer Healthcare and India Distribution. Sun Pharma was founded by her father, Dilip Shanghvi in 1983. They started making psychiatric drugs and slowly became India's most valuable pharma company, with a market capitalisation of Rs 3.95 lakh crore. Vidhi was recently appointed as Whole-time Director for a five-year term. Vidhi Shanghvi Educational Background Vidhi graduated from the Wharton School at the University of Pennsylvania. In Sun Pharma, she used her education in marketing and consumer healthcare. She began her career at Sun Pharma in 2012 as a Brand Manager in the India Business division. Over the years, she has held several leadership positions. In 2014, she became the Marketing Head for one of the company's Cardiovascular Business Units. She also handled many marketing campaigns. After the merger of Ranbaxy with Sun Pharma, Vidhi Shanghvi became the Business Head of the company's Consumer Healthcare Division. She has played a big role in the growth of the products like Revital H and Volini in retail stores, pharmacies, and online platforms in India. She also has expertise in various fields like marketing, brand building, project and alliance management, and distribution. She is the founder of Mann Talks, a not-for-profit mental health initiative. This platform gives free, holistic mental health solutions to individuals for their mental well-being.
Time of India
18-06-2025
- Business
- Time of India
Meet Vidhi Shanghvi, daughter of India's richest pharma tycoon, steering a Rs 3.95 lakh crore company
Vidhi Shanghvi, daughter of India's pharma tycoon Dilip Shanghvi, is making headlines for her impressive role in Sun Pharma, one of India's biggest pharmaceutical companies. With a net worth of $25 billion, Dilip Shanghvi is India's richest pharma billionaire and among the top 100 richest people in the world. But now, all eyes are on his daughter Vidhi Shanghvi, who is slowly stepping into the limelight with her strong leadership and modern approach to business. Who is Vidhi Shanghvi? Vidhi Shanghvi is currently the Executive Director at Sun Pharma, a company founded by her father, Dilip Shanghvi in 1983. Sun Pharma started as a maker of psychiatric drugs and has grown to become India's most valuable pharma company, with a market capitalisation of ₹3.95 lakh crore. Vidhi was recently appointed as Whole-time Director for a five-year term, showing her growing influence within the company. Educational Background of Vidhi Shanghvi Following the footsteps of many billionaire heirs, Vidhi Shanghvi studied abroad to gain global exposure. She graduated from the prestigious Wharton School at the University of Pennsylvania, a top business school in the world. Her academic background has helped her bring fresh and innovative ideas to Sun Pharma, especially in areas like marketing and consumer healthcare. Career Journey at Sun Pharma Vidhi Shanghvi began her career at Sun Pharma in 2012 as a Brand Manager in the India Business division. Over the years, she has held several leadership positions. In 2014, she became the Marketing Head for one of the company's Cardiovascular Business Units. She led many successful marketing campaigns and was instrumental in improving business operations and initiating digital transformation projects. Leading Sun Pharma's Consumer Healthcare and Distribution In 2015, after the merger of Ranbaxy with Sun Pharma, Vidhi Shanghvi was made the Business Head of the company's Consumer Healthcare Division. Under her leadership, this division has grown rapidly. She has played a key role in boosting the presence of popular products like Revital H and Volini across retail stores, pharmacies, and online platforms in India. Apart from Consumer Healthcare, Vidhi Shanghvi also leads India Distribution – a crucial part of Sun Pharma's value chain. Her efforts have helped improve supply efficiency and expand reach across the country. Over 13 Years of Experience in Pharma Sector With more than 13 years of professional experience, Vidhi Shanghvi has built expertise in various fields, including marketing, brand building, project and alliance management, and distribution. Her dynamic leadership style and strategic thinking have earned her recognition within the industry. Vidhi Shanghvi's Passion for Mental Health Beyond her corporate role at Sun Pharma, Vidhi Shanghvi is also deeply committed to mental health. She is the founder of Mann Talks, a not-for-profit mental health initiative. This platform provides free, holistic mental health solutions and encourages individuals to take charge of their mental well-being. What is Dilip Shanghvi's Net Worth? Dilip Shanghvi, founder of Sun Pharma, has an estimated net worth of $25.8 billion, according to Forbes. As of today, June 18, he is the 77th richest person in the world and remains one of the most successful entrepreneurs in India. His vision and leadership have shaped Sun Pharma into a global pharmaceutical giant. Vidhi Shanghvi's Brother Also Plays a Key Role Vidhi Shanghvi's brother, Aalok Shanghvi, is also part of the leadership at Sun Pharma. A few months ago, he was promoted to the position of Chief Operating Officer (COO), making it a truly family-led business. Vidhi Shanghvi is clearly following in the footsteps of her father Dilip Shanghvi, but she is also building her own legacy at Sun Pharma. With a strong academic background, diverse industry experience, and a clear passion for healthcare and innovation, Vidhi Shanghvi is emerging as a powerful new-age leader in the Indian pharmaceutical sector.
Time of India
18-06-2025
- Business
- Time of India
Meet Vidhi Shanghvi, daughter of India's richest pharma billionaire
Vidhi Shanghvi, daughter of India's pharma tycoon Dilip Shanghvi, is making headlines for her impressive role in Sun Pharma, one of India's biggest pharmaceutical companies. With a net worth of $25 billion, Dilip Shanghvi is India's richest pharma billionaire and among the top 100 richest people in the world. But now, all eyes are on his daughter Vidhi Shanghvi, who is slowly stepping into the limelight with her strong leadership and modern approach to business. Who is Vidhi Shanghvi? Vidhi Shanghvi is currently the Executive Director at Sun Pharma, a company founded by her father, Dilip Shanghvi in 1983. Sun Pharma started as a maker of psychiatric drugs and has grown to become India's most valuable pharma company, with a market capitalisation of ₹3.95 lakh crore. Vidhi was recently appointed as Whole-time Director for a five-year term, showing her growing influence within the company. Educational Background of Vidhi Shanghvi Following the footsteps of many billionaire heirs, Vidhi Shanghvi studied abroad to gain global exposure. She graduated from the prestigious Wharton School at the University of Pennsylvania, a top business school in the world. Her academic background has helped her bring fresh and innovative ideas to Sun Pharma, especially in areas like marketing and consumer healthcare. Career Journey at Sun Pharma Vidhi Shanghvi began her career at Sun Pharma in 2012 as a Brand Manager in the India Business division. Over the years, she has held several leadership positions. In 2014, she became the Marketing Head for one of the company's Cardiovascular Business Units. She led many successful marketing campaigns and was instrumental in improving business operations and initiating digital transformation projects. Leading Sun Pharma's Consumer Healthcare and Distribution In 2015, after the merger of Ranbaxy with Sun Pharma, Vidhi Shanghvi was made the Business Head of the company's Consumer Healthcare Division. Under her leadership, this division has grown rapidly. She has played a key role in boosting the presence of popular products like Revital H and Volini across retail stores, pharmacies, and online platforms in India. Apart from Consumer Healthcare, Vidhi Shanghvi also leads India Distribution – a crucial part of Sun Pharma's value chain. Her efforts have helped improve supply efficiency and expand reach across the country. Over 13 Years of Experience in Pharma Sector With more than 13 years of professional experience, Vidhi Shanghvi has built expertise in various fields, including marketing, brand building, project and alliance management, and distribution. Her dynamic leadership style and strategic thinking have earned her recognition within the industry. Vidhi Shanghvi's Passion for Mental Health Beyond her corporate role at Sun Pharma, Vidhi Shanghvi is also deeply committed to mental health. She is the founder of Mann Talks, a not-for-profit mental health initiative. This platform provides free, holistic mental health solutions and encourages individuals to take charge of their mental well-being. What is Dilip Shanghvi's Net Worth? Dilip Shanghvi, founder of Sun Pharma, has an estimated net worth of $25.8 billion, according to Forbes. As of today, June 18, he is the 77th richest person in the world and remains one of the most successful entrepreneurs in India. His vision and leadership have shaped Sun Pharma into a global pharmaceutical giant. Vidhi Shanghvi's Brother Also Plays a Key Role Vidhi Shanghvi's brother, Aalok Shanghvi, is also part of the leadership at Sun Pharma. A few months ago, he was promoted to the position of Chief Operating Officer (COO), making it a truly family-led business. Vidhi Shanghvi is clearly following in the footsteps of her father Dilip Shanghvi, but she is also building her own legacy at Sun Pharma. With a strong academic background, diverse industry experience, and a clear passion for healthcare and innovation, Vidhi Shanghvi is emerging as a powerful new-age leader in the Indian pharmaceutical sector. For the latest and more interesting financial news, keep reading Indiatimes Worth. Click here
